Profile data is unavailable for this security.
About the company
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
- Revenue in USD (TTM)62.30m
- Net income in USD-165.00m
- Incorporated2009
- Employees284.00
- LocationNurix Therapeutics Inc1700 Owens St Ste 205SAN FRANCISCO 94158-0006United StatesUSA
- Phone+1 (415) 660-5320
- Fax+1 (415) 525-4200
- Websitehttps://www.nurixtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gyre Therapeutics Inc | 165.85m | -79.66m | 1.26bn | 593.00 | -- | 19.09 | -- | 7.59 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Cassava Sciences Inc | 0.00 | -15.37m | 1.30bn | 29.00 | -- | 6.87 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Enliven Therapeutics Inc | 0.00 | -82.83m | 1.30bn | 52.00 | -- | 4.26 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.38bn | 23.00 | -- | 6.39 | -- | 2,751.20 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Kura Oncology Inc | 0.00 | -181.75m | 1.38bn | 142.00 | -- | 2.96 | -- | -- | -2.23 | -2.23 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -36.00 | -26.04 | -38.16 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0198 | -- | -- | -- | -12.36 | -- | -- | -- |
Xencor Inc | 133.62m | -177.37m | 1.39bn | 280.00 | -- | 2.17 | -- | 10.38 | -2.90 | -2.90 | 2.19 | 9.14 | 0.1666 | -- | 6.35 | 477,207.20 | -22.40 | -3.70 | -24.25 | -4.12 | -- | -- | -134.45 | -15.92 | -- | -- | 0.0331 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.41bn | 50.00 | -- | 4.78 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Nurix Therapeutics Inc | 62.30m | -165.00m | 1.43bn | 284.00 | -- | 3.85 | -- | 22.95 | -2.92 | -2.92 | 1.10 | 5.76 | 0.1446 | -- | -- | 219,376.80 | -38.30 | -33.01 | -46.57 | -39.66 | -- | -- | -264.84 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Dynavax Technologies Corp | 249.70m | 17.18m | 1.44bn | 408.00 | 108.99 | 2.25 | 66.66 | 5.78 | 0.1011 | 0.1011 | 1.76 | 4.91 | 0.2557 | 0.7766 | 4.76 | 611,997.60 | 1.76 | 4.16 | 1.86 | 5.71 | 82.03 | 64.83 | 6.88 | 9.19 | 13.18 | -- | 0.2578 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Spyre Therapeutics Inc | 0.00 | -185.98m | 1.48bn | 50.00 | -- | 6.77 | -- | -- | -15.42 | -15.42 | 0.00 | 7.37 | 0.00 | -- | -- | 0.00 | -54.73 | -101.87 | -87.47 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
Disc Medicine Inc | 0.00 | -91.00m | 1.48bn | 74.00 | -- | 3.03 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Rocket Pharmaceuticals Inc | 0.00 | -253.26m | 1.49bn | 268.00 | -- | 3.88 | -- | -- | -2.79 | -2.79 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -55.77 | -35.26 | -60.57 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0522 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Arcus Biosciences Inc | 247.00m | -249.00m | 1.52bn | 577.00 | -- | 2.39 | -- | 6.16 | -3.10 | -3.10 | 3.02 | 6.96 | 0.2053 | -- | 7.06 | 428,076.30 | -20.70 | -15.85 | -24.57 | -18.25 | -- | -- | -100.81 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Belite Bio Inc (ADR) | 0.00 | -35.29m | 1.56bn | 20.00 | -- | 13.62 | -- | -- | -1.23 | -1.23 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -39.40 | -- | -39.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
BioCryst Pharmaceuticals Inc | 382.24m | -145.93m | 1.57bn | 536.00 | -- | -- | -- | 4.10 | -0.7301 | -0.7301 | 1.90 | -2.30 | 0.7627 | 0.3747 | 6.05 | 713,126.90 | -29.12 | -47.95 | -37.43 | -64.89 | 98.46 | 97.06 | -38.18 | -114.94 | 2.78 | -0.6999 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
Syndax Pharmaceuticals Inc | 3.50m | -264.08m | 1.60bn | 112.00 | -- | 3.68 | -- | 457.58 | -3.38 | -3.38 | 0.0447 | 5.11 | 0.0077 | -- | 0.6132 | 31,250.00 | -58.15 | -27.90 | -63.20 | -30.15 | -- | -- | -7,545.20 | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 31 Mar 2024 | 4.48m | 6.97% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 3.88m | 6.03% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.85m | 5.99% |
Deep Track Capital LPas of 31 Mar 2024 | 3.00m | 4.66% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.73m | 4.24% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.55m | 3.96% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.36m | 3.66% |
ARK Investment Management LLCas of 30 Jun 2024 | 2.32m | 3.61% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.13m | 3.32% |
DWS Investments (UK) Ltd.as of 31 Mar 2024 | 1.50m | 2.33% |